Our Clinical Approach to Medical Weight Loss

A step-by-step look at how we evaluate, dose, monitor, and adjust care for every patient we treat.

Our clinical approach to medical weight loss starts with a full intake and history review, then an individualized eligibility decision before any prescription. We dose conservatively, start low and go slow, schedule regular check-ins to manage side effects, protect muscle through nutrition guidance, and adjust or pause treatment when your body asks us to. We treat the patient, not a number on a scale.

What happens during the intake and history review?

Before I write a single prescription, I want to understand the person in front of me. The intake covers your weight history, what you have already tried, and what actually happened when you tried it. We review current medications, past surgeries, family history, and any conditions that change how a medication behaves in your body.

I ask about the things people sometimes leave off forms: thyroid problems, a history of pancreatitis, gallbladder disease, a personal or family history of medullary thyroid cancer, eating-disorder history, pregnancy plans, and how alcohol fits into your week. Some of these are reasons to choose a different path. Some simply change how cautiously we move. The point of a careful history is not to disqualify you. It is to make the plan safe enough that you can stay on it.

Why is eligibility individualized instead of automatic?

Two people can weigh the same and still need very different plans. One has well-controlled blood pressure and a desk job. The other has reflux, a sensitive stomach, and a history of kidney stones. A responsible clinic does not run everyone through the same template.

Eligibility for GLP-1 medications like compounded semaglutide and compounded tirzepatide depends on your health profile, not just a BMI cutoff. I weigh the likely benefit against the specific risks you carry. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions, and results vary by individual. That honesty is part of the eligibility conversation, not a footnote to it. If I do not think a medication is right for you yet, I will tell you, and I will explain why.

Why do you start low and go slow with dosing?

The fastest way to make someone quit a GLP-1 medication is to push the dose too hard, too early. The nausea, the fatigue, the days of feeling off: most of that comes from rushing. So we do the opposite.

We begin at a low starting dose and increase only when your body has settled at the current step. There is no prize for reaching a high dose quickly. The goal is the lowest effective dose that gives you steady progress with side effects you can live with. For many people that means staying at a modest dose longer than they expected, and doing better for it. The trial evidence is encouraging: in the STEP-1 trial, semaglutide produced an average of about 14.9 percent of body weight lost, and in SURMOUNT-1, tirzepatide averaged about 20.9 percent. Those are averages from studies, not promises for your particular body, and they were reached through gradual titration, not a sprint.

How do you manage side effects and check in?

Most GLP-1 side effects are predictable and manageable when someone is actually paying attention. Nausea, constipation, early fullness, and reflux tend to show up in the first weeks and after dose increases. We plan for them rather than react to them.

• Regular check-ins so we catch problems early instead of at a crisis point.
• Practical adjustments like smaller meals, hydration targets, and timing changes before we touch the dose.
• Clear instructions on which symptoms warrant a message to us and which warrant urgent care.

You are not meant to white-knuckle through misery and hope it passes. If something feels wrong, I would rather hear about it on day three than at the next scheduled visit. Because we are a telehealth clinic, reaching us does not require taking a half-day off work.

How do you protect muscle and guide nutrition?

Weight loss is not the same thing as fat loss. When the scale drops fast, some of that loss can come from muscle, and losing muscle is not a win. It slows your metabolism and makes the weight easier to regain later. So nutrition guidance is built into the plan, not bolted on at the end.

We focus on getting enough protein, eating it across the day rather than in one sitting, and pairing the medication with resistance activity that you can realistically keep up. Appetite drops on these medications, which is the point, but it also means you can quietly undereat protein without noticing. Part of my job is to keep that from happening. Strength matters as much as the number on the scale, and a plan that ignores it is incomplete.

When and why would you adjust or pause treatment?

A good plan is a living thing. We adjust when side effects outpace benefit, when progress stalls in a way that suggests a different lever is needed, or when life events such as surgery, illness, or pregnancy plans change the calculus. Pausing is not failure. Sometimes it is the most clinically sound decision available.

We also watch for plateaus honestly. A plateau can mean the dose needs revisiting, or it can mean your body has found a new set point worth holding for a while. Either way, the response is a conversation grounded in your data, not an automatic dose increase. If a medication stops being the right tool, we say so.

What will you not promise?

I will not promise a guaranteed number of pounds, a guaranteed timeline, or that you will land at the high end of any trial. Some marketing leans on certainty because certainty sells. Medicine cannot honestly offer it. Results vary by individual, and anyone who tells you otherwise is selling, not treating.

What I can promise is a real clinical relationship: a physician who reviews your history, dosing that respects your body, monitoring that catches trouble early, and the integrity to pause or change course when that serves you better than pushing forward. The SELECT trial showed a cardiovascular benefit for semaglutide in adults with established cardiovascular disease and overweight or obesity, which is meaningful, but it describes a studied population, not a guarantee for everyone.

What does this cost and how do I start?

We are a cash-pay, bilingual, HIPAA-private telehealth clinic, so there is no insurance to wrangle. A visit is $119. Compounded semaglutide is $166 per month, roughly $5.50 a day, with a 90-day Reset at $499. Compounded tirzepatide is $233 per month, about $7.70 a day, with a 90-day Reset at $699. If you want to test the waters first, the $199 Skeptics Trial covers one month.

You can reach New Hope Weight Loss and Wellness at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626. Call (657) 837-3342 in English or (213) 214-3325 in Spanish. The brand medications referenced in this category, Ozempic and Wegovy (Novo Nordisk) and Mounjaro and Zepbound (Eli Lilly), are not affiliated with our clinic, and the compounded medications we use are not identical to them.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.